Levomepromazine

Geriatric
  • TRADE NAME: Nozinan (Sanofi-Aventis)
  • INDICATIONS: Pain, anxiety and distress in people with terminal illness, psychosis, schizophrenia
  • SYNONYM: methotrimeprazine
  • CLASS: Antipsychotic, Neuroleptic, Phenothiazine
  • HALF-LIFE: ~20 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

ACE inhibitors, Adrenergic neurone blockers, Alcohol, Alpha blockers, Amantadine, Amiodarone, Angiotensin II receptor antagonists, Antacids, Antiarrhythmics prolonging QT interval, Antimuscarinics, Antiolytics and hypnotics, Apomorphine, Arsenic, Artemether/Lumefantrine, Atomoxetine, Barbiturates, Beta blockers, Bromocriptine, Cabergoline, Caffeine, Calcium channel blockers, Carbamazepine, Cimetidine, Clonidine, Cyclobenzaprine, Diazoxide, Disopyramide, Diuretics, Dronedarone, Droperidol, Duloxetine, Efavirenz, Ephedrine, Eszopiclone, Ethosuximide, General anesthetics, Histamine, Hydralazine, Kaolin, Levodopa, Lithium, Lurasidone, Memantine, Metaxalone, Methyldopa, Metoclopramide, Milnacipran, Minoxidil, Moxifloxacin, Moxonidine, Myelosuppressives, Nitrates, Nitroprusside, Opioid analgesics, Oxcarbazepine, Paliperidone, Pentamidine, Pergolide, Phenytoin, Pimozide, Pramipexole, Primidone, Ramelteon, Ritonavir, Ropinirole, Rotigotine, Saquinavir, Sodium Oxybate, Sodium Phenylbutyrate, Sotalol, Succinylcholine, Sulfonylureas, Sympathomimetics, Tetrabenazine, Tiagabine, Tramadol, Tricyclic antidepressants, Valproic Acid

NOTE

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Nozinan is not indicated for the treatment of patients with dementia-related psychosis.

Contraindicated in cases of coma or CNS depression due to alcohol, hypnotics, analgesics or narcotics; also in patients with blood dyscrasia, hepatic problems or a sensitivity to phenothiazines.

Not available in the USA.

Our database has 16 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.


Page last updated 08/03/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top